Jacob Johnson
Stock Analyst at Stephens & Co.
(2.88)
# 1,795
Out of 5,090 analysts
75
Total ratings
45.76%
Success rate
9.15%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $261.02 | -8.05% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.59 | -8.88% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $7.76 | -22.68% | 4 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $35.00 | +71.43% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $227.13 | +38.69% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $575.24 | +18.21% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $165.54 | +2.70% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $4.77 | +4.82% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.59 | +594.01% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $22.92 | +65.79% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.80 | +73.47% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.09 | +19.62% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $63.37 | +37.29% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $281.77 | +38.41% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $12.13 | +48.45% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.77 | +239.94% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $25.75 | +12.62% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $184.04 | +104.85% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $261.02
Upside: -8.05%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.59
Upside: -8.88%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $7.76
Upside: -22.68%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $35.00
Upside: +71.43%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $227.13
Upside: +38.69%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $575.24
Upside: +18.21%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $165.54
Upside: +2.70%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $4.77
Upside: +4.82%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.59
Upside: +594.01%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $22.92
Upside: +65.79%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.80
Upside: +73.47%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.09
Upside: +19.62%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $63.37
Upside: +37.29%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $281.77
Upside: +38.41%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $12.13
Upside: +48.45%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.77
Upside: +239.94%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $25.75
Upside: +12.62%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $184.04
Upside: +104.85%